Table 2. Descriptive characteristics of the study participants by endocrine Resistance/Sensitivity* (N:161).
| Overall population | Endocrine-Resistant Patients 64 (39.75) | Endocrine-Responsive Patients 97 (36.6) | p |
|---|---|---|---|
| N(%)§ | |||
|
Age <65 ≥65 |
31(48.4) 33(51.6) |
36(37.1) 52(53.6) |
0.36 |
|
ECOG PS 0 1-2 |
49 (79.0) 13(21.0) |
58(59.8) 27(27.8) |
0.15 |
|
BMI <25 ≥25 |
35(54.7) 29(45.3) |
32 (33.0) 56 (57.7) |
0.02 |
|
ER 30 <30 ≥30 |
2(3.1) 61(95.3) |
11(11.3) 67(69.1) |
0.03 |
|
PgR negative positive |
8(12.5) 56(87.5) |
11(11.3) 77(79.4) |
1.0 |
|
HER2 negative positive |
54(84.4) 9(14.1) |
80(82.5) 4(4.1) |
0.04 |
|
Ki-67 <15 ≥15 Grade 1-2 3 |
23(35.9) 38(59.4) 40(62.5) 18(28.1) |
34(35.0) 43(44.3) 55(56.7) 22(22.7) |
0.45 0.76 |
|
Fulvestrant given in 1st line 2nd or subsequent Visceral Involvement no yes Number of metastatic sites 1 >1 Bone involvement No Yes |
42(65.6) 22(34.4) 32(50.0) 32(50.0) 29(45.3) 35(54.7) 43(67.2) 21(32.8) |
30(30.9) 58(59.8) 52(53.6) 36(37.1) 47(48.4) 41(42.3) 61(62.8) 27(27.8) |
<0.0001 0.27 0.32 0.78 |
*Patients were considered endocrine resistant if recurrence occurred during or within 12 months after the end of adjuvant treatment or progression was recorded while on or within 1 month after the completion of treatment for advanced disease.
§Percentages may not add up to 100 because of missing values
BMI: body mass index, ER and/or PgR: estrogen and/or progesterone receptor; ER: estrogen receptor; PgR: progesterone receptor.